Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML

Plain-language summary

This research examines how the interaction between gut microbiota and tyrosine kinase inhibitors (TKIs) affects clinical outcomes in patients with chronic myeloid leukemia (CML). Patients over 18 years old with CML at any stage may take part. It is a non-phase observational study using biological samples that is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Carmen Fava

Intervention

non interventional study with the use of biological samples.

Start date

10/1/2022

Estimated completion

10/1/2026

Countries

Italy

Related genes

Locations

• Torino, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age \> 18 years old
* Chronic Myeloid Leukemia Patients
* Any stage of the disease

Exclusioni Criteria:

none